Overview
MindMed is a clinical-stage psychedelic medicine company developing novel therapeutics derived from LSD, MDMA, and ibogaine analogs for neurological and psychiatric disorders. Their lead asset MM120 (LSD tartrate) has shown promising Phase 2b results for generalized anxiety disorder.
More in Psychedelics
Latest industry news
Precision Neuroscience Raises $250M to Accelerate Brain-Computer Interface Development
2026-11-01 · Funding
Merge Labs Gets Competition as New Rival Neurotech Startup Enters the Consumer BCI Arena
2026-10-31 · Industry
Neuralink Connects to Grok AI Agent, Enabling ALS Patient to Control AI and Make Calls by Thought Alone
2026-10-30 · Product
Implanted BCIs Still Lack a Shared Safety Rulebook, and the Field Is Running Out of Time to Write One
2026-10-29 · Research
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →